Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma in Europe.
In advanced cutaneous T-cell lymphoma (CTCL), allogeneic stem cell transplant is the only curative option, but many patients are ineligible and relapse after systemic therapy, requiring retreatment with prior therapies. Brentuximab vedotin (BV), an anti-CD30 monoclonal antibody drug conjugated with monomethyl auristati...